Cyclosporine A in the long-term management of systemic lupus erythematosus

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 3, 2011, Pages 397-403

  Germano, Valentina ^a   Picchianti Diamanti, A ^a   Ferlito, C ^a   Podesta E ^a   Salemi, S ^a   Migliore, A ^b   D'Amelio, R ^a   Lagana B ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Unit of Rheumatology S Peter Hospital FBF   (Italy)

Author keywords

Cyclosporine A; Systemic lupus erythematosus disease activity index

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE;

ABDOMINAL PAIN; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; FOLLOW UP; GUM HYPERTROPHY; HUMAN; HYPERTENSION; HYPERTRICHOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ADULT; CYCLOSPORINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 80755142783     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. D'Cruz DPD, Khamashta MA, Hughes GRV. Systemic lupus erythematosus The Lancet 2007; 369:587-96. (Pubitemid 46241445)
2. Miescher PA, Favre H, Lemoine R, Huang YP. Drug combination therapy of systemic lupus erythematosus. Springer Semin Immunopathol 1994; 16:295-311.
3. Nannini C, Crowson CS, Matteson EL, Moder KG. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study. Lupus 2009; 18:395-99.
4. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Ramsey-Goldman. Mortality in systemic lupus erythematosus. Arthritis and Rheum 2006; 54:2250-57.
5. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929-39. (Pubitemid 351397092)
6. Kimberly RP. Research advances in systemic lupus erythematosus. JAMA 2001; 285:650-1. (Pubitemid 32656341)
7. Ioannou Y, Isenberg DA. Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad Med J 2002; 78:599-606. (Pubitemid 35333066)
8. Isenberg DA, Snaith ML, Morrow WJ, et al. Cyclosporyne A for the treatment of SLE. Int J Immunopharmacol 1981; 3:163-9.
9. Caccavo D, Lagana B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, Bonomo L. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum 1997; 40:27-35. (Pubitemid 27044033)
10. Zhang C, Zhang J, Yang B, Wu C. Cyclosporin A inhibits the production of IL-17 by memory Th17 cells from healthy individuals and patients with rheumatoid arthritis. Cytokine 2008; 42:345-52.
11. Richaud-Patin Y, Soto-Vega E, Jakez-Ocampo J, Llorente L. P-glycoprotein in autoimune diseases. Autoimmunity Rew 2004; 3:188-92.
12. Tokuda M, Kurata N, Mizoguchi A, Inoh M, Seto K, Kinashi M, Takahara J. Effect of low-dose cyclosporin A on systemic lupus erythematosus disease activity. Arthritis Rheum 1994; 37:551-58. (Pubitemid 24115942)
13. Tan EM, Cohen AS, Fries JF, Alfonse TM, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271-77. (Pubitemid 13221242)
14. Tewthanom K, Janwityanuchit S, Totemchockchyakarn K, Panomvana D. Correlation of lipid peroxidation and glutathione levels with severity of systemic lupus erythematosus: a pilot study from single center. J Pharm Pharm Sci 2008; 11:30-34.
15. Mosca M, Bombardieri S. Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol 2006; 24:99-104.
16. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35:630-40.
17. Miescher PA, Zavota L, Ossandon A, Lagana B. Autoimmune disorders: a concept of treatment based on mechanisms of disease. Springer Semin Immunopathol 2003; 1(S):5-60.
18. Churg J, Sobin L. Renal disease: classification and altas of glomerular disease. Tokyo: Igaku-Shoin 1982.
19. Moroni G, Doria A, Mosca M, et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol 2006; 1:925-32.
20. Ogawa H, Kameda H, Nagasawa H, Sekiguchi N, Takei H, Tsuzaka K, Amano K, Takeuchi T. Prospective study of low-dose cyclosporine A in patients with refractory lupus nephritis. Mod Rheumatol 2007; 17:92-97. (Pubitemid 46614351)
21. Manger K, Kalden JR, Manger B. Cyclosporin A in the treatment of systemic lupus erythematosus: results of an open clinical study. Br J Rheumatol 1996; 35:669-75.
22. Moroni G. CSA in lupus nephritis: assessing the evidence. Nephrol Dial Transplant 2009; 24:15-20.
23. Ogawa H. Efficacy and safety of CSA in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus 2010; 19:162-69.
24. Coaccioli S, Giuliani M, Puxeddu A. The therapy of Sjogren's syndrome: a review. Clin Ter 2007; 158:453-56. (Pubitemid 351315171)
25. Morton SJ, Powell RJ. An audit of cyclosporin for systemic lupus erythematosus and related overlap syndromes: limitations of its use. Ann Rheum Dis 2000; 59:487-89. (Pubitemid 30395608)
26. Lavrnic D, Vujic A, Rakocevic-Stojanovic V, Stevic Z, Basta I, Pavlovic S, Trikic R, Apostolski S. Cyclosporine in the treatment of myasthenia gravis. Acta Neurol Scand 2005; 111:247-52. (Pubitemid 40380460)